Clarger

Antibacterial

Description
Shipping Options
Customer Reviews

Clarger is an injectable form of Clarithromycin, a macrolide antibiotic used for severe bacterial infections when oral administration is not feasible.

Composition

Active Ingredient: Clarithromycin – 500 mg/vial (as Clarithromycin Lactobionate).
Excipients: May include lactose, sodium hydroxide (for pH adjustment).

Mechanism of Action

Bacteriostatic (inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit).
Effective against:
- Gram-positive bacteria (Staphylococcus aureus, Streptococcus pneumoniae).
- Atypical pathogens (Mycoplasma, Legionella, Chlamydia).
- Some Gram-negative bacteria (H. influenzae, Moraxella catarrhalis).
- Mycobacteria (Mycobacterium avium complex – MAC).

Dosage & Administration

Adults:

500 mg every 12 hours (IV infusion over 60 minutes).
Switch to oral therapy as soon as clinically appropriate.

Renal/Hepatic Impairment:

Severe renal impairment (CrCl <30 mL/min): Reduce dose by 50% (e.g., 250 mg 12 hourly).
Liver disease: Use with caution (risk of QT prolongation).

Pediatrics:

Not typically recommended for IV use in children (prefer oral suspension).

Uses (Indications)

Severe respiratory tract infections (pneumonia, exacerbations of chronic bronchitis).
Community-acquired pneumonia (CAP) (including atypical pneumonia).
Mycobacterial infections (e.g., MAC in HIV patients).
Skin & soft tissue infections (SSTI).
H. pylori eradication (in combination therapy).

Storage

Unreconstituted vials: Store below 25°C, protect from light & moisture.
Reconstituted solution:
- Stable for 24 hours at 2–8°C (refrigerated).
- Use immediately if stored at room temperature.
Do not freeze.

Recommendations

Monitor liver enzymes & ECG (risk of hepatotoxicity & QT prolongation).
Avoid in patients with known macrolide allergy.
Drug interactions:
- CYP3A4 inhibitors/inducers (e.g., ketoconazole, rifampin).
- Warfarin (increased INR risk).
- Statins (risk of rhabdomyolysis).

Important Note

Not first-line for severe sepsis (prefer beta-lactams in critically ill patients).
Pregnancy (Category C): Use only if benefits outweigh risks.
QT Prolongation Risk: Avoid in patients with arrhythmias or electrolyte imbalances.
IV-to-Oral Switch: Transition as soon as possible to reduce complications.

Side Effects

Common: Nausea, diarrhea, metallic taste, injection site reactions.
Serious: Hepatotoxicity, QT prolongation, C. difficile colitis.

Clarger is an injectable form of Clarithromycin, a macrolide antibiotic used for severe bacterial infections when oral administration is not feasible.

Composition

Active Ingredient: Clarithromycin – 500 mg/vial (as Clarithromycin Lactobionate).
Excipients: May include lactose, sodium hydroxide (for pH adjustment).

Mechanism of Action

Bacteriostatic (inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit).
Effective against:
- Gram-positive bacteria (Staphylococcus aureus, Streptococcus pneumoniae).
- Atypical pathogens (Mycoplasma, Legionella, Chlamydia).
- Some Gram-negative bacteria (H. influenzae, Moraxella catarrhalis).
- Mycobacteria (Mycobacterium avium complex – MAC).

Dosage & Administration

Adults:

500 mg every 12 hours (IV infusion over 60 minutes).
Switch to oral therapy as soon as clinically appropriate.

Renal/Hepatic Impairment:

Severe renal impairment (CrCl <30 mL/min): Reduce dose by 50% (e.g., 250 mg 12 hourly).
Liver disease: Use with caution (risk of QT prolongation).

Pediatrics:

Not typically recommended for IV use in children (prefer oral suspension).

Uses (Indications)

Severe respiratory tract infections (pneumonia, exacerbations of chronic bronchitis).
Community-acquired pneumonia (CAP) (including atypical pneumonia).
Mycobacterial infections (e.g., MAC in HIV patients).
Skin & soft tissue infections (SSTI).
H. pylori eradication (in combination therapy).

Storage

Unreconstituted vials: Store below 25°C, protect from light & moisture.
Reconstituted solution:
- Stable for 24 hours at 2–8°C (refrigerated).
- Use immediately if stored at room temperature.
Do not freeze.

Recommendations

Monitor liver enzymes & ECG (risk of hepatotoxicity & QT prolongation).
Avoid in patients with known macrolide allergy.
Drug interactions:
- CYP3A4 inhibitors/inducers (e.g., ketoconazole, rifampin).
- Warfarin (increased INR risk).
- Statins (risk of rhabdomyolysis).

Important Note

Not first-line for severe sepsis (prefer beta-lactams in critically ill patients).
Pregnancy (Category C): Use only if benefits outweigh risks.
QT Prolongation Risk: Avoid in patients with arrhythmias or electrolyte imbalances.
IV-to-Oral Switch: Transition as soon as possible to reduce complications.

Side Effects

Common: Nausea, diarrhea, metallic taste, injection site reactions.
Serious: Hepatotoxicity, QT prolongation, C. difficile colitis.

Shipping Options –

We offer a variety of shipping options, including Express Mail Service (EMS), USPS, DHL, FedEx, TNT, UPS, Aramex, Air Cargo, and sea freight.

Terms and Conditions –

Bulk Orders: You are responsible for any local import duties and taxes in your country.

For Patients: When ordering prescription medicines for personal use, or for a friend or relative, a valid medical practitioner’s script or prescription is required.

Return and Refund Policy: Due to the nature of our products, we cannot accept returns or exchanges once a purchase is made. However, in the event of non-delivery, you are eligible for either a 100% refund or a reshipment of your order.

Description
Reviews (0)

Clarger is an injectable form of Clarithromycin, a macrolide antibiotic used for severe bacterial infections when oral administration is not feasible.

Composition

Active Ingredient: Clarithromycin – 500 mg/vial (as Clarithromycin Lactobionate).
Excipients: May include lactose, sodium hydroxide (for pH adjustment).

Mechanism of Action

Bacteriostatic (inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit).
Effective against:
- Gram-positive bacteria (Staphylococcus aureus, Streptococcus pneumoniae).
- Atypical pathogens (Mycoplasma, Legionella, Chlamydia).
- Some Gram-negative bacteria (H. influenzae, Moraxella catarrhalis).
- Mycobacteria (Mycobacterium avium complex – MAC).

Dosage & Administration

Adults:

500 mg every 12 hours (IV infusion over 60 minutes).
Switch to oral therapy as soon as clinically appropriate.

Renal/Hepatic Impairment:

Severe renal impairment (CrCl <30 mL/min): Reduce dose by 50% (e.g., 250 mg 12 hourly).
Liver disease: Use with caution (risk of QT prolongation).

Pediatrics:

Not typically recommended for IV use in children (prefer oral suspension).

Uses (Indications)

Severe respiratory tract infections (pneumonia, exacerbations of chronic bronchitis).
Community-acquired pneumonia (CAP) (including atypical pneumonia).
Mycobacterial infections (e.g., MAC in HIV patients).
Skin & soft tissue infections (SSTI).
H. pylori eradication (in combination therapy).

Storage

Unreconstituted vials: Store below 25°C, protect from light & moisture.
Reconstituted solution:
- Stable for 24 hours at 2–8°C (refrigerated).
- Use immediately if stored at room temperature.
Do not freeze.

Recommendations

Monitor liver enzymes & ECG (risk of hepatotoxicity & QT prolongation).
Avoid in patients with known macrolide allergy.
Drug interactions:
- CYP3A4 inhibitors/inducers (e.g., ketoconazole, rifampin).
- Warfarin (increased INR risk).
- Statins (risk of rhabdomyolysis).

Important Note

Not first-line for severe sepsis (prefer beta-lactams in critically ill patients).
Pregnancy (Category C): Use only if benefits outweigh risks.
QT Prolongation Risk: Avoid in patients with arrhythmias or electrolyte imbalances.
IV-to-Oral Switch: Transition as soon as possible to reduce complications.

Side Effects

Common: Nausea, diarrhea, metallic taste, injection site reactions.
Serious: Hepatotoxicity, QT prolongation, C. difficile colitis.

Reviews

There are no reviews yet.

Be the first to review “Clarger ”

Description
Reviews (0)

Clarger is an injectable form of Clarithromycin, a macrolide antibiotic used for severe bacterial infections when oral administration is not feasible.

Composition

Active Ingredient: Clarithromycin – 500 mg/vial (as Clarithromycin Lactobionate).
Excipients: May include lactose, sodium hydroxide (for pH adjustment).

Mechanism of Action

Bacteriostatic (inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit).
Effective against:
- Gram-positive bacteria (Staphylococcus aureus, Streptococcus pneumoniae).
- Atypical pathogens (Mycoplasma, Legionella, Chlamydia).
- Some Gram-negative bacteria (H. influenzae, Moraxella catarrhalis).
- Mycobacteria (Mycobacterium avium complex – MAC).

Dosage & Administration

Adults:

500 mg every 12 hours (IV infusion over 60 minutes).
Switch to oral therapy as soon as clinically appropriate.

Renal/Hepatic Impairment:

Severe renal impairment (CrCl <30 mL/min): Reduce dose by 50% (e.g., 250 mg 12 hourly).
Liver disease: Use with caution (risk of QT prolongation).

Pediatrics:

Not typically recommended for IV use in children (prefer oral suspension).

Uses (Indications)

Severe respiratory tract infections (pneumonia, exacerbations of chronic bronchitis).
Community-acquired pneumonia (CAP) (including atypical pneumonia).
Mycobacterial infections (e.g., MAC in HIV patients).
Skin & soft tissue infections (SSTI).
H. pylori eradication (in combination therapy).

Storage

Unreconstituted vials: Store below 25°C, protect from light & moisture.
Reconstituted solution:
- Stable for 24 hours at 2–8°C (refrigerated).
- Use immediately if stored at room temperature.
Do not freeze.

Recommendations

Monitor liver enzymes & ECG (risk of hepatotoxicity & QT prolongation).
Avoid in patients with known macrolide allergy.
Drug interactions:
- CYP3A4 inhibitors/inducers (e.g., ketoconazole, rifampin).
- Warfarin (increased INR risk).
- Statins (risk of rhabdomyolysis).

Important Note

Not first-line for severe sepsis (prefer beta-lactams in critically ill patients).
Pregnancy (Category C): Use only if benefits outweigh risks.
QT Prolongation Risk: Avoid in patients with arrhythmias or electrolyte imbalances.
IV-to-Oral Switch: Transition as soon as possible to reduce complications.

Side Effects

Common: Nausea, diarrhea, metallic taste, injection site reactions.
Serious: Hepatotoxicity, QT prolongation, C. difficile colitis.

Reviews

There are no reviews yet.

Be the first to review “Clarger ”

Medical Disclaimer

Anteka Pharmacy primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on Anteka Pharmacy. Our mission is to support, not replace, the doctor-patient relationship.